HemaSphere (Jun 2022)
S216: CLINICAL ACTIVITY OF CC-99282, A CEREBLON E3 LIGASE MODULATOR (CELMOD) AGENT, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA (R/R NHL) – RESULTS FROM A PHASE 1, OPEN-LABEL STUDY
- J.-M. Michot,
- J. C. Chavez,
- C Carpio,
- S. Ferrari,
- T. A. Feldman,
- D. Morillo,
- J. Kuruvilla,
- A. Pinto,
- V. Ribrag,
- E Bachy,
- T. J. Buchholz,
- S. Carrancio,
- W.-C. Chou,
- C. Guarinos,
- F. Wu,
- S. Li,
- P. Patah,
- M. Pourdehnad,
- L. Nastoupil
Affiliations
- J.-M. Michot
- 1 Département d’Innovation Thérapeutique et d’Essais Précoces (DITEP), Gustave Roussy Institute of Cancer, Villejuif, France
- J. C. Chavez
- 2 Department of Malignant Hematology, Moffitt Cancer Center, University of South Florida, Tampa, United States of America
- C Carpio
- 3 Department of Hematology, Vall d’Hebron Institute of Oncology (VHIO), University Hospital Vall d’Hebron, Autonomous University of Barcelona (UAB), Barcelona, Spain
- S. Ferrari
- 4 Hematology and Bone Marrow Transplant Unit, ASST Papa Giovanni XXIII, Bergamo, Italy
- T. A. Feldman
- 5 Lymphoma Division, John Theurer Cancer Center at Hackensack Meridian Health, Hackensack, United States of America
- D. Morillo
- 6 Department of Hematology, University Hospital Fundación Jiménez Díaz, Madrid, Spain
- J. Kuruvilla
- 7 Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada
- A. Pinto
- 8 Hematology-Oncology & Stem Cell Transplantation Unit, National Cancer Institute, Fondazione G. Pascale, IRCCS, Naples, Italy
- V. Ribrag
- 1 Département d’Innovation Thérapeutique et d’Essais Précoces (DITEP), Gustave Roussy Institute of Cancer, Villejuif, France
- E Bachy
- 9 Department of Hematology, Hospices Civils de Lyon, Lyon, France
- T. J. Buchholz
- 10 Early Clinical Development, Oncology, Bristol Myers Squibb, San Francisco
- S. Carrancio
- 11 Oncogenesis (ONC) Thematic Research Center (TRC), Bristol Myers Squibb, San Diego
- W.-C. Chou
- 12 Early Development Predictive Sciences, Bristol Myers Squibb, Cambridge, United States of America
- C. Guarinos
- 13 ONC TRC-Celgene Institute for Translational Research Europe (CITRE), Bristol Myers Squibb, Seville, Spain
- F. Wu
- 14 Clinical Pharmacology & Pharmacometrics, Bristol Myers Squibb, Summit
- S. Li
- 15 Global Biometric Sciences, Bristol Myers Squibb, Berkley Heights
- P. Patah
- 16 Early Clinical Development, Bristol Myers Squibb, Lawrenceville
- M. Pourdehnad
- 17 Early Clinical Development, Hematology/Oncology and Cell Therapy, Bristol Myers Squibb, San Francisco
- L. Nastoupil
- 18 Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, United States of America
- DOI
- https://doi.org/10.1097/01.HS9.0000843756.99251.20
- Journal volume & issue
-
Vol. 6
pp. 117 – 118
Abstract
No abstracts available.